399 filings
Page 3 of 20
6-K
SPRC
SciSparc Ltd
16 Oct 23
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
4:01pm
6-K
SPRC
SciSparc Ltd
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
SPRC
SciSparc Ltd
3 Oct 23
SciSparc Granted European Patent for its Core Technology
7:35am
6-K
SPRC
SciSparc Ltd
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
SPRC
SciSparc Ltd
21 Sep 23
SciSparc Announces 1-for-26 Reverse Share Split
6:31am
6-K
SPRC
SciSparc Ltd
19 Sep 23
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
6:16pm
6-K
SPRC
SciSparc Ltd
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
144
Revach Moshe
21 Aug 23
Notice of proposed sale of securities
5:14pm
6-K
SPRC
SciSparc Ltd
18 Aug 23
Report of Foreign Private Issuer
4:01pm
6-K
SPRC
SciSparc Ltd
14 Aug 23
Supplemental Proxy Statement
5:29pm
6-K
SPRC
SciSparc Ltd
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
424B5
SPRC
SciSparc Ltd
14 Aug 23
Prospectus supplement for primary offering
9:14am
424B3
SPRC
SciSparc Ltd
10 Aug 23
Prospectus supplement
6:32am
6-K
SPRC
SciSparc Ltd
9 Aug 23
SciSparc Ltd. Announces Proposed Underwritten Public Offering of Approximately $1.3 Million
7:30pm
424B3
SPRC
SciSparc Ltd
9 Aug 23
Prospectus supplement
4:01pm
6-K
SPRC
SciSparc Ltd
2 Aug 23
Report of Foreign Private Issuer
12:00am
6-K
SPRC
SciSparc Ltd
17 Jul 23
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
8:00am
6-K
SPRC
SciSparc Ltd
11 Jul 23
Report of Foreign Private Issuer
4:16pm
6-K
SPRC
SciSparc Ltd
30 Jun 23
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
4:10pm
6-K
SPRC
SciSparc Ltd
26 Jun 23
Report of Foreign Private Issuer
4:04pm